Unknown PHASE1 INTERVENTIONAL 1-arm NCT05441046

Genakumab Alone and in Combination With Tislelizumab in Patients With Advanced Malignant Solid Tumors

Phase I and Extended Clinical Study of Safety, Tolerability, and Pharmacokinetics of Injectable Genakumab Alone and Combination With Tislelizumab in the Treatment of Advanced Malignant Solid Tumors

Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.

Conditions Malignant Solid Tumors

Interventions Genakumab

Updated 5 times since 2022 Last updated: Jul 3, 2022 Started: Jun 7, 2022 Primary completion: Jun 30, 2024 Completion: Mar 31, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Malignant Solid Tumors and is currently ongoing. Changchun GeneScience Pharmaceutical Co., Ltd. leads this study, which shows 5 recorded versions since 2022 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Apr 2025 — Present [monthly]

Unknown PHASE1

Status: Recruiting → Unknown
Sep 2024 — Apr 2025 [monthly]

Recruiting PHASE1
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1
Oct 2023 — Jul 2024 [monthly]

Recruiting PHASE1
Sep 2022 — Oct 2023 [monthly]

Recruiting PHASE1

First recorded

Jun 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Changchun GeneScience Pharmaceutical Co., Ltd.

Data source: Changchun GeneScience Pharmaceutical Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hangzhou, China